STOCK TITAN
  1. Home
  2. News
  3. CATX

Perspective Therapeutics, Inc. - $CATX STOCK NEWS

Welcome to our dedicated page for Perspective Therapeutics news (Ticker: $CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Perspective Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Perspective Therapeutics's position in the market.

News
Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine
Rhea-AI Summary
Perspective Therapeutics presents encouraging early clinical results for [212Pb]VMT-α-NET therapy in patients with neuroendocrine tumors and medullary thyroid carcinomas. Initial response seen in 7 out of 9 evaluable patients. Responses observed in both PRRT-naïve and PRRT-refractory disease. No significant adverse events observed. Potential for expansion into other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
clinical trial
-
News
Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine
Rhea-AI Summary
[212Pb]VMT-α-NET shows promise in treating neuroendocrine tumors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
Rhea-AI Summary
Perspective Therapeutics to present at World Molecular Imaging Congress 2023, showcasing positive results for lead-based alpha particle therapies in treating neuroendocrine tumors and image-guided pre-targeted alpha particle therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences
News
Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine
Rhea-AI Summary
Perspective Therapeutics to present new clinical and preclinical data for 212Pb-VMT-α-NET at EANM conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
conferences clinical trial
-
News
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
Rhea-AI Summary
Perspective Therapeutics announces the dosing of the first patient in their Phase 1/2a dose escalation trial for 212Pb-VMT01 in patients with MC1R+ metastatic melanoma. The trial aims to evaluate the safety and efficacy of the targeted alpha-particle therapy. Preliminary data from the study is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
clinical trial
-
News
Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
Rhea-AI Summary
Perspective Therapeutics, Inc. reports Q2 2023 financial results and highlights progress in their pipeline. Phase 1/2a clinical trials initiated for VMT-α-NET and VMT01. Preliminary results expected by end of 2023. Multiple appointments made in key leadership roles. Australian subsidiary launched for early-stage clinical R&D work. Positive data on VMT01 presented at medical conferences. Favorable comparison of Cesium-131 brachytherapy in prostate cancer. Increase in reimbursement rates for Cesium-131 seeds proposed by CMS. Manufacturing and supply milestones achieved. Decline in revenue and gross profit. Increase in R&D expenses. Net loss of $11.1 million in Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
earnings
News
Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
News
Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
-
News
Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
clinical trial
News
Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.56%
Tags
none
Stock CATX logo
Perspective Therapeutics, Inc.

NYSE:CATX

CATX Rankings

#2467 Ranked by Market Cap
#3097 Ranked by Stock Gains
N/A Ranked by Dividends

CATX Stock Data

989.98M
393.11M
23.41%
7.06%
1.38%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
SEATTLE

About CATX

the introduction of cesium-131 represents the culmination of decades of work and millions of dollars of investment. top medical centers, hospitals and clinics across the united states are now offering this breakthrough treatment for cancer patients. the word brachytherapy derives from the greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. pioneers in brachytherapy research initially theorized about the use of cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and iodine-125 emerged as an alternative. beginning in 1967, iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. while its use continues to this day, many patients and doct